Recall of Xenform Soft Tissue Repair Matrix 8cm x 12cm

According to Department of Health, Therapeutic Goods Administration, this recall involved a device in Australia that was produced by Boston Scientific Pty Ltd.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
    Recall
  • Event ID
    RC-2016-RN-00823-1
  • Event Risk Class
    Class II
  • Event Initiated Date
    2016-06-17
  • Event Country
  • Event Source
    DHTGA
  • Event Source URL
  • Notes / Alerts
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Extra notes in the data
  • Reason
    Xenform soft tissue repair matrix is currently supplied to customers who have tga (therapeutic goods administration) approval through the special access scheme (sas). on wednesday 15th june 2016, boston scientific (“bsc”) identified that units of xenform soft tissue repair matrix were shipped from the australian bsc distribution centre to some customers who did not have the appropriate sas approval in place.
  • Action
    Boston Scientific is advising users to quarantine affected stock for return. A credit note will be issued for all returned product.

Device

  • Model / Serial
    Xenform Soft Tissue Repair Matrix 8cm x 12cmMaterial Number: M0068302470Batch Number: 1602010Expiry Date: 30 November 2018Supplied through the Special Access Scheme (SAS)ARTG Number: 174878
  • Manufacturer

Manufacturer

  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “We take a patient-first approach to assessing the applicability of every recall and communicate to regulatory bodies in all geographies where the recalled device is sold,” Boston Scientific said in a statement to ICIJ. “We have coordinated several recalls across many countries in a timely manner,” the company said, adding that it complies with all national laws, which can often vary and require different processes for reporting information or taking action on recalls. The company said it uses a rigorous and uniform process to take action on recalls and that “when we initiate a field action (e.g. recall, safety alert), every customer who has received an affected product receives a communication that includes a letter for the physician.”
  • Source
    DHTGA